Vanda Pharmaceuticals (VNDA) to Release Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is scheduled to release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.18) per share for the quarter.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The business had revenue of $50.47 million during the quarter. On average, analysts expect Vanda Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $4.74 on Thursday. The firm has a fifty day moving average price of $4.86 and a two-hundred day moving average price of $5.23. Vanda Pharmaceuticals has a one year low of $3.30 and a one year high of $6.75. The company has a market cap of $276.29 million, a price-to-earnings ratio of -24.00 and a beta of 0.77.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 24th. They issued a “hold” rating for the company. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $18.00 price target for the company. Finally, Cantor Fitzgerald raised their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.